Funding Opportunity RFA-AG-19-019 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications for the next 5-year cycle of the National Health and Aging Trends Study (NHATS), the leading nationally representative, longitudinal, data resource in the US for research on trends, dynamics, and disparities in late-life disability, and for studies of the social and economic consequences of late-life disability for individuals, families and society, including caregiving and end-of-life issues. NHATS has conducted seven annual rounds of data collection to date (an eighth round is in process) and is linked to the separately-funded National Study of Caregiving (NSOC). The goals of the next cycle are to 1) Continue the current structure and design elements of NHATS; 2) Permit studies of long-term trends in disability prevalence; 3) Enrich measurement of cognitive capacity; 4) Enhance measurement of physical activity and sedentary behavior; 5) Continue linkages with administrative records; and 6) Augment data dissemination and user support.

competitive: Celgene: Seeking a Principal Scientist, Bioinformatics / Single-Cell for the San Diego, CA location. San Diego, California (US)

Doctoral degree (PhD, ScD, or equivalent) in Computer Science, Biomedical Informatics, Bioinformatics, Computational Biology, or a closely related quantitative...
From University of Wisconsin–Madison - Sun, 01 Jul 2018 06:58:52 GMT - View all Madison, WI jobs

Notice NOT-DA-18-021 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-087 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-18-845 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs.

Funding Opportunity PAR-18-846 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs.

Funding Opportunity PAR-18-847 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.

Funding Opportunity PAR-18-848 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.

Notice NOT-HL-18-632 from the NIH Guide for Grants and Contracts

Notice NOT-DA-18-023 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-079 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-078 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-18-025 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory and developmental research projects to uncover functional roles of non-coding RNAs (ncRNAs) in viral infectious diseases. Importantly, the projects should focus on functional characterization and mechanistic studies of previously identified ncRNAs. Applications limited to the discovery or identification of ncRNAs will not be supported under this RFA.

Funding Opportunity RFA-AI-18-022 from the NIH Guide for Grants and Contracts. The Purpose of this Funding Opportunity Announcement is to solicit applications to rapidly implement early clinical trials using native and/or engineered monoclonal antibodies (mAbs) to achieve a drug-free sustained virologic remission in HIV infected individuals.

Funding Opportunity PA-18-842 from the NIH Guide for Grants and Contracts. The purpose of this trans-NCI Funding Opportunity Announcement (FOA) is to promote new cancer disparities research among investigators who do not normally conduct it and to encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. This FOA is intended to accelerate and strengthen multi-disciplinary cancer disparities research in wide-ranging areas. Cancer disparities research includes, but is not limited to basic, translational, behavioral, observational, interventional, environmental and population research studies that address the adverse differences in cancer incidence, prevalence, mortality, survivorship, burden and/or response to treatment in racial/ethnic minorities and/or underserved population groups. Proposed collaborations should focus on achieving research objectives that by necessity rely on diverse and complementary expertise, technical capabilities, and resource sets. Importantly, the supplemental proposal is required to be within the scope of the parent award and should expand the original aims to include a cancer disparity component.

Notice NOT-CA-18-088 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-18-841 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations. Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease. Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource.

Notice NOT-HL-18-637 from the NIH Guide for Grants and Contracts

Negotiable: Paramount Recruitment: Director of Computational Biology, Cancer Immunology Connecticut, United States Pharmaceutical, Translational Bioinformatics A global pharmaceu Connecticut, USA